TD Asset Management
FBRX icon

TD Asset Management’s Forte Biosciences FBRX Stock Holding History

TD Asset Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-70
Closed -$175K – 1342
2019
Q2 		$175K Sell
70
-20
-22% -$59.3K ﹤0.01% 1305
2019
Q1 		$368K Hold
90
– – ﹤0.01% 1238
2018
Q4 		$278K Buy
90
+27
+43% +$116K ﹤0.01% 1313
2018
Q3 		$370K Buy
63
+15
+31% +$57.1K ﹤0.01% 1344
2018
Q2 		$169K Hold
48
– – ﹤0.01% 1396
2018
Q1 		$215K Buy
48
+1
+2% +$4.63K ﹤0.01% 1309
2017
Q4 		$179K Buy
47
+12
+34% +$47.9K ﹤0.01% 1309
2017
Q3 		$164K Hold
35
– – ﹤0.01% 1278
2017
Q2 		$158K Buy
+35
New +$197K ﹤0.01% 1316

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TD Asset Management's FBRX Position: Q3 2019 in Review

TD Asset Management sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 70 shares — an estimated $175K sold.

TD Asset Management first reported a position in FBRX in Q2 2017 and held it in 9 quarters. The position peaked at $370K in Q3 2018. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

  • TD Asset Management reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
  • TD Asset Management sold 70 Forte Biosciences shares in Q3 2019, an estimated $175K.
  • TD Asset Management first reported a position in Forte Biosciences in Q2 2017 and held it in 9 quarters.
  • TD Asset Management's Forte Biosciences position peaked at $370K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on TD Asset Management's 13F filing for Q3 2019, filed 7 Nov 2019.